Literature DB >> 30498986

Depotentiation of Long-Term Potentiation Is Associated with Epitope-Specific Tau Hyper-/Hypophosphorylation in the Hippocampus of Adult Rats.

Ercan Babür1, Burak Tan1, Sumeyra Delibaş1, Marwa Yousef1, Nurcan Dursun1, Cem Süer2,3.   

Abstract

It is well-known that some kinases which are involved in the induction of synaptic plasticity probably modulate tau phosphorylation. However, how depression of potentiated synaptic strength contributes to tau phosphorylation is unclear because of the lack of experiments in which depotentiation of LTP was induced. Field excitatory postsynaptic potential (fEPSP) and population spike (PS) were recorded from the dentate gyrus in response to the perforant pathway stimulation. To induce LTP, high-frequency stimulation (HFS) was used, while, for depotentiation of LTP, low-frequency stimulation (LFS) consisting of 900 pulses at 1 Hz was applied 5 min after tetanization. In some experiments, a neutral protocol at 0.033 Hz was applied throughout the experiment without any induction of synaptic plasticity. One-hertz depotentiation protocol was able to decrease fEPSP slope which was previously increased by HFS, whereas no significant change in fEPSP slope and PS amplitude was observed in neutral protocol experiments. Relative to saline infusion, LTP was lower in magnitude and was more reversed by subsequent LFS in the presence of ERK1/2 inhibitor. Western blot experiments indicated that tau protein was hyperphosphorylated at ser416 epitope but rather hypophosphorylated at thr231 epitope in the whole hippocampus upon depotentiation of LTP. These changes concomitantly occurred with a notable increase in the levels of total tau and in the levels of phosphorylated form of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). ERK1/2 inhibition resulted in a decrease in phosphorylation of tau at p416Tau when ERK1/2 was inhibited. These findings indicate that some forms of long-term plastic changes might be related with epitope-specific tau phosphorylation and ERK1/2 activation in the hippocampus. Therefore, we emphasize that tau may be crucial for physiological learning as well as Alzheimer's disease pathology.

Entities:  

Keywords:  Alzheimer’s disease pathology; Depotentiation; Extracellular signal-regulated protein kinases 1/2; Hippocampus; Tau proteins

Mesh:

Substances:

Year:  2018        PMID: 30498986     DOI: 10.1007/s12031-018-1224-x

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  55 in total

1.  Differential roles of Ca(2+)/calmodulin-dependent protein kinase II and mitogen-activated protein kinase activation in hippocampal long-term potentiation.

Authors:  J Liu; K Fukunaga; H Yamamoto; K Nishi; E Miyamoto
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

2.  Low-frequency stimulation erases LTP through an NMDA receptor-mediated activation of protein phosphatases.

Authors:  T J O'Dell; E R Kandel
Journal:  Learn Mem       Date:  1994 Jul-Aug       Impact factor: 2.460

3.  A selective role of calcineurin aalpha in synaptic depotentiation in hippocampus.

Authors:  M Zhuo; W Zhang; H Son; I Mansuy; R A Sobel; J Seidman; E R Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

4.  Dual MAP kinase pathways mediate opposing forms of long-term plasticity at CA3-CA1 synapses.

Authors:  V Y Bolshakov; L Carboni; M H Cobb; S A Siegelbaum; F Belardetti
Journal:  Nat Neurosci       Date:  2000-11       Impact factor: 24.884

5.  Dendritic spikes as a mechanism for cooperative long-term potentiation.

Authors:  Nace L Golding; Nathan P Staff; Nelson Spruston
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

6.  Biphasic modulation of hippocampal plasticity by behavioral stress and basolateral amygdala stimulation in the rat.

Authors:  I Akirav; G Richter-Levin
Journal:  J Neurosci       Date:  1999-12-01       Impact factor: 6.167

7.  A role for extracellular adenosine in time-dependent reversal of long-term potentiation by low-frequency stimulation at hippocampal CA1 synapses.

Authors:  C C Huang; Y C Liang; K S Hsu
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

8.  Reduction of calcineurin activity in brain by antisense oligonucleotides leads to persistent phosphorylation of tau protein at Thr181 and Thr231.

Authors:  T D Garver; R L Kincaid; R A Conn; M L Billingsley
Journal:  Mol Pharmacol       Date:  1999-04       Impact factor: 4.436

9.  Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease.

Authors:  X Zhu; C A Rottkamp; H Boux; A Takeda; G Perry; M A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2000-10       Impact factor: 3.685

10.  Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.

Authors:  Mitsuko Hashiguchi; Taro Saito; Shin-ichi Hisanaga; Toshio Hashiguchi
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

View more
  4 in total

1.  Tau is required for the function of extrasynaptic NMDA receptors.

Authors:  Noemí Pallas-Bazarra; Jonathan Draffin; Raquel Cuadros; José Antonio Esteban; Jesús Avila
Journal:  Sci Rep       Date:  2019-06-24       Impact factor: 4.379

2.  Long-term depression-related tau phosphorylation is enhanced by methylene blue in healthy rat hippocampus.

Authors:  Cem Süer; Nurbanu Yıldız; Özlem Barutçu; Burak Tan; Nurcan Dursun
Journal:  Pharmacol Rep       Date:  2021-04-02       Impact factor: 3.024

3.  Rho-associated kinases contribute to the regulation of tau phosphorylation and amyloid metabolism during neuronal plasticity.

Authors:  Hatice Saray; Cem Süer; Bilal Koşar; Burak Tan; Nurcan Dursun
Journal:  Pharmacol Rep       Date:  2021-06-01       Impact factor: 3.024

4.  Aluminum and Tau in Neurofibrillary Tangles in Familial Alzheimer's Disease.

Authors:  Matthew John Mold; Adam O'Farrell; Benjamin Morris; Christopher Exley
Journal:  J Alzheimers Dis Rep       Date:  2021-04-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.